Compare Liberty Global Ltd Class C (LBTYK) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Global Ltd Class C vs Twist Bioscience Corp — how do they compare? Liberty Global Ltd Class C trades at $10.07 (market cap $3.47B), while Twist Bioscience Corp trades at $93.5 (market cap $5.45B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals.
| LBTYK | TWST | |
|---|---|---|
Market Cap | $3.47B | $5.45B |
Sector | Technology | Health |
52-Week High | $12.67 | $102.88 |
52-Week Low | $10.00 | $24.16 |
Enterprise Value | $10.75B | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LBTYK trades at $9.995, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $7.14 billion for 2025, though revenue grew to $4.88 billion. Recent news highlights strategic moves, including the planned 2027 Amsterdam listing of Ziggo Group. Analyst consensus is strongly positive, with 69% recommending Buy.
The outlook hinges on execution of the Ziggo Group spin-off, a potential value catalyst. However, persistent losses and high debt-to-asset ratio of 38.39% pose significant risks. The stock offers a deep value opportunity if management delivers on restructuring, but operational turnaround is critical for sustained recovery.
Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.
The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
